---
title: "Emergence and Spread of Cryptosporidium hominis gp60 IfA12G1R5 in Spain"
id: "cdc-emerging-infectious-diseases-journal-1-post-covid-19-emergence-and-spread-of-hypertransmissible-cryptosporidium"
canonical_url: "https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-1-post-covid-19-emergence-and-spread-of-hypertransmissible-cryptosporidium"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "CDC Emerging Infectious Diseases Journal"
source_url: "https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article"
published_at: "2026-11-02T05:00:00.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Emergence and Spread of Cryptosporidium hominis gp60 IfA12G1R5 in Spain
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-1-post-covid-19-emergence-and-spread-of-hypertransmissible-cryptosporidium
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** CDC Emerging Infectious Diseases Journal
- **Source URL:** [Original Journal Publication](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article)
- **Published At:** 2026-11-02T05:00:00.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- Investigators reviewed published molecular data and multicenter clinical samples to compare pre- and post–COVID-19 Cryptosporidium subtype distributions in Spain. - Prepandemic (2000–2019) the cohort showed predominance of **Cryptosporidium hominis**, with subtype family Ib (largely IbA10G2) accounting for the vast majority of isolates across multiple studies and settings. - During December 2013–December 2019, national reference laboratory genotyping of clinical samples (n reported in source) confirmed IbA10G2 dominance among **C. hominis** and IIa predominance among **C. parvum**. - Postpandemic sampling (March–December 2023) across multiple tertiary hospitals found a marked shift: **C. hominis** remained dominant but subtype family If (all If isolates = **IfA12G1R5**) rose to 70.2% within C. hominis and 67.5% overall in 2023 sequence deposits. - The historically predominant IbA10G2 declined sharply, from approximately 79.7% (historical data) to 1.6% in 2023 clinical sequences; IbA13G3 increased within family Ib in the postpandemic set. - **C. parvum** detection was comparatively rare in 2023, and cases that were detected belonged to subtype family IIa. - Data indicated increased subtype diversity in 2023 (10 subtypes) versus earlier years (2–5 subtypes), suggesting rapid subtype turnover after relaxation of containment measures. - The authors reported that pandemic nonpharmaceutical interventions disproportionately interrupted anthroponotic transmission networks, producing a dual epidemiologic scenario with stable zoonotic transmission versus disrupted human-to-human spread. - The source noted a postpandemic cryptosporidiosis resurgence across Europe and referenced potential contributors (for example, immunity debt), but the article did not provide quantitative measures or mechanistic evidence for those contributors. - Limitations and unanswered questions in the source include the absence of detailed transmission chains, precise sampling denominators in all regions, and mechanistic data linking pandemic-era interventions to specific subtype selection pressures.
## Clinical Analysis & Structured Key Points
[Skip directly to page options](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#share-nav) [Skip directly to A-Z link](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#az-large) ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png) An official website of the United States government Here's how you know ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg) **Official websites use .gov** A .gov website belongs to an official government organization in the United States. ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg) **Secure .gov websites use HTTPS** A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. [CDC Home](https://wwwnc.cdc.gov/) [ ![Centers for Disease Control and Prevention](https://wwwnc.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg) ](https://www.cdc.gov/) Emerging Infectious Diseases ![](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) Search Dropdown × Submit Emerging Infectious Diseases * [About the Journal](https://wwwnc.cdc.gov/eid/about) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **About the Journal** * [General Information](https://wwwnc.cdc.gov/eid/about/general) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **General Information** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **About the Journal****General Information** * [Background and Goals](https://wwwnc.cdc.gov/eid/about/background) * [Editors](https://wwwnc.cdc.gov/eid/about/editors) * [Editorial Board](https://wwwnc.cdc.gov/eid/about/editorial-board) * [Staff](https://wwwnc.cdc.gov/eid/about/staff) * [ Home](https://wwwnc.cdc.gov/) * [Contact](https://wwwnc.cdc.gov/eid/contact) * [EID Journal Report 2025](https://wwwnc.cdc.gov/eid/pdfs/JournalReport_2025.pdf) * [ Home](https://wwwnc.cdc.gov/) * [Articles](https://wwwnc.cdc.gov/eid/) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Articles** * [November 2026](https://wwwnc.cdc.gov/eid/current) * [Wastewater Surveillance](https://wwwnc.cdc.gov/eid/articles/issue/32/13/table-of-contents) * [Early Release](https://wwwnc.cdc.gov/eid/early-release) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Early Release** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Articles****Early Release** * [Post–COVID-19 Emergence and Spread of Hypertransmissible Cryptosporidium hominis gp60 Subtype IfA12G1R5, Spain](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Post–COVID-19 Emergence and Spread of Hypertransmissible Cryptosporidium hominis gp60 Subtype IfA12G1R5, Spain** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Early Release****Post–COVID-19 Emergence and Spread of Hypertransmissible Cryptosporidium hominis gp60 Subtype IfA12G1R5, Spain** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Articles****Early Release****Post–COVID-19 Emergence and Spread of Hypertransmissible Cryptosporidium hominis gp60 Subtype IfA12G1R5, Spain** * [Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1) * [Table 2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t2) * [Table 3](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t3) * [Appendix](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf) * [ Home](https://wwwnc.cdc.gov/) * [ Home](https://wwwnc.cdc.gov/) * [Past Issues](https://wwwnc.cdc.gov/eid/past-issues/volume-32) * [Medscape CME](https://wwwnc.cdc.gov/eid/articles/cme) * [ICEID](https://wwwnc.cdc.gov/eid/page/iceid) * [ Home](https://wwwnc.cdc.gov/) * [Search](https://wwwnc.cdc.gov/eid/Search) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Search** * [Advanced Article Search](https://wwwnc.cdc.gov/eid/AdvancedSearch) * [Articles by Country Search](https://wwwnc.cdc.gov/eid/ArticleMap) * [Spotlight Topics](https://wwwnc.cdc.gov/eid/spotlight) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Spotlight Topics** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Search****Spotlight Topics** * [Antimicrobial Resistance Spotlight](https://wwwnc.cdc.gov/eid/spotlight/antimicrobial-resistance) * [Coronavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/coronavirus) * [Ebola Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ebola) * [Etymologia](https://wwwnc.cdc.gov/eid/articles/etymologia) * [Foodborne Diseases and Outbreaks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/foodborne-diseases) * [Fungal Diseases](https://wwwnc.cdc.gov/eid/spotlight/fungal) * [Hantavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hantavirus) * [HIV/AIDS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hiv) * [Influenza Spotlight](https://wwwnc.cdc.gov/eid/spotlight/influenza) * [Lyme Disease Spotlight](https://wwwnc.cdc.gov/eid/spotlight/lyme-disease) * [Malaria Spotlight](https://wwwnc.cdc.gov/eid/spotlight/malaria) * [MERS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mers) * [Mpox Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mpox) * [Pneumonia Spotlight](https://wwwnc.cdc.gov/eid/spotlight/pneumonia) * [Rabies Spotlight](https://wwwnc.cdc.gov/eid/spotlight/rabies) * [Ticks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ticks) * [Tuberculosis/Mycobacteria](https://wwwnc.cdc.gov/eid/spotlight/tuberculosis) * [Zika Spotlight](https://wwwnc.cdc.gov/eid/spotlight/zika) * [ Home](https://wwwnc.cdc.gov/) * [Article Type Search](https://wwwnc.cdc.gov/eid/ArticleTypeSearch) * [EID on PubMed Central](https://www.ncbi.nlm.nih.gov/pmc/journals/782/) * [ Home](https://wwwnc.cdc.gov/) * [Subscribe](https://wwwnc.cdc.gov/eid/subscriptions) * [Author Resource Center](https://wwwnc.cdc.gov/eid/page/author-resource-center) * [Peer Reviewers](https://wwwnc.cdc.gov/eid/reviewers) * [Podcasts](https://wwwnc.cdc.gov/eid/podcasts) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) **Podcasts** * [Search](https://wwwnc.cdc.gov/eid/podcasts/search) * [ Home](https://wwwnc.cdc.gov/) * [Social Media](https://wwwnc.cdc.gov/eid/page/social-media) * [ Press & Media Information](https://wwwnc.cdc.gov/eid/press) * [ Home](https://wwwnc.cdc.gov/) 1. [EID Journal](https://wwwnc.cdc.gov/eid/) 2. [Volume 32](https://wwwnc.cdc.gov/eid/early-release) 3. [Early Release](https://wwwnc.cdc.gov/eid/early-release#issue-1348) 4. [Main Article](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) * [Facebook](https://www.facebook.com/sharer/sharer.php?u=%2Feid%2Farticle%2F32%2F12%2F26-1007_article "Share to Facebook") * [Twitter](http://twitter.com/share?url=%2Feid%2Farticle%2F32%2F12%2F26-1007_article&text= "Share to Twitter") * [LinkedIn](https://www.linkedin.com/shareArticle?url=%2Feid%2Farticle%2F32%2F12%2F26-1007_article&title= "Share to LinkedIn") * [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent//eid/article/32/12/26-1007_article "Embed this Page") [ Emerging Infectious Disease journal ISSN: 1080-6059 ](https://wwwnc.cdc.gov/eid/) _Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released._ #### Volume 32, Number 12—December 2026 ##### _Dispatch_ ### Post–COVID-19 Emergence and Spread of Hypertransmissible _Cryptosporidium hominis gp60_ Subtype IfA12G1R5, Spain On This Page [The Study](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) * * * [Conclusions](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) * * * [Suggested Citation](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) Tables [Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1) * * * [Table 2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t2) * * * [Table 3](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t3) Downloads [Appendix ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf) * * * [RIS [TXT - 2 KB] ](https://wwwnc.cdc.gov/eid/article/32/12/26-1007.ris) Article Metrics [Metric Details](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) Related Articles [Human _Armillifer armillatus_ Infection Mimicking Strangulated Umbilical Hernia, France, 2026](https://wwwnc.cdc.gov/eid/article/32/12/26-1471_article) * * * [_Dirofilaria asiatica_ Asymptomatic Microfilaremia](https://wwwnc.cdc.gov/eid/article/32/11/26-0015_article) * * * [_Dirofilaria asiatica_ Infection in 2-Year-Old Child](https://wwwnc.cdc.gov/eid/article/32/11/26-0739_article) * * * [More articles on Parasites](https://wwwnc.cdc.gov/eid/spotlight/parasites) Lidia Goterris[1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#fn1), Pamela C. Köster[1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#fn1), Julia Fuentes, Elena Sulleiro, Marina Alguacil-Guillén, Miriam J. Álvarez-Martínez, Alba Llop, Gema Fernández-Rivas, Anabel Fernández-Navarro, Isabel Fradejas, Guillermo Ruiz-Carrascoso, Nuria Prim-Bosch, Alba Bellés-Bellés, José M. Azcona-Gutiérrez, Ana Pérez-Ayala, Oihane Martín, Aida de Lucio, Begoña Bailo, Lourdes Castro-Companioni, Rocío Martínez-Ruiz, Francisco J. Merino, Gemma J. Muñoz de-Mier, Israel Molina, Sergio Sánchez[2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#fn2), and David Carmena[2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#fn2)[![Comments to Author](https://wwwnc.cdc.gov/eid/content/images/icon/email.gif)](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#comment) Author affiliation: Vall d'Hebron University Hospital, Barcelona, Spain (L. Goterris, J. Fuentes, E. Sulleiro, I. Molina); Health Institute Carlos III, Majadahonda, Spain (P.C. Köster, A. de Lucio, B. Bailo, L. Castro-Companioni, S. Sánchez, D. Carmena); Alfonso X el Sabio University, Villanueva de la Cañada, Spain (P.C. Köster, G.J. Muñoz-de-Mier); Hospital Clinic of Barcelona, Barcelona (M. Alguacil-Guillén, M.J. Álvarez-Martínez); Germans Trias i Pujol Hospital, Badalona, Spain (A. Llop, G. Fernández-Rivas, A. Fernández-Navarro); Alcorcon Foundation Hospital, Alcorcón, Spain (I. Fradejas); La Paz University Hospital, Madrid (G. Ruiz-Carrascoso); Centre for Biomedical Research Network in Infectious Diseases, Madrid (G. Ruiz-Carrascoso, I. Molina, D. Carmena); Bellvitge University Hospital, Bellvitge, Spain (N. Prim-Bosch); Arnau de Vilanova University Hospital, Lleida, Spain (A. Bellés-Bellés); San Pedro University Hospital, Logroño, Spain (J.M. Azcona-Gutiérrez); 12 de Octubre University Hospital, Madrid (A. Pérez-Ayala); University Hospital Ramón y Cajal, Madrid (O. Martín); Puerta de Hierro University Hospital of Majadahonda, Majadahonda (R. Martínez-Ruiz); Severo Ochoa University Hospital, Leganés, Spain (F.J. Merino) [Suggested citation for this article](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#suggestedcitation) ### Abstract COVID-19 pandemic containment measures in 2020 selectively altered established _Cryptosporidium hominis_ anthroponotic transmission in Spain. Rapid emergence and expansion of hypertransmissible human-adapted _gp60_ subtypes such as IfA12G1R5 and, less markedly, IbA13G3 followed. Conversely, transmission of the largely zoonotic _C. parvum_ remained comparatively stable, yielding a dual epidemiologic scenario in this country. Cryptosporidiosis is a public health concern in Europe; outbreaks have been linked to contaminated drinking water, recreational water, and fresh produce ([_1_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r1 "1"),[_2_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r2 "2")). In 2020, the European Union reported 1.7 confirmed cases/100,000 population ( [External Link](https://www.ecdc.europa.eu/en/publications-data/cryptosporidiosis-annual-epidemiological-report-2020)), although the true burden is likely underestimated because of underdiagnosis and underreporting. The COVID-19 pandemic and associated nonpharmaceutical interventions altered the epidemiology of gastrointestinal pathogens ([_3_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r3 "3")). The effects of those measures on _Cryptosporidium_ species varied, as shown in time-series analyses comparing prepandemic and postpandemic incidence of cryptosporidiosis and molecular data from countries in Europe (England, Scotland, and Wales) and New Zealand ([_4_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r4 "4")–[ _6_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r6 "6")). Furthermore, a postpandemic study in Spain of young children with diarrhea demonstrated an interruption in the transmission of _C. hominis_ , but not _C. parvum_ ([_7_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r7 "7")). We collated prepandemic and postpandemic molecular data from published literature and from multicenter, nonoutbreak studies to investigate the molecular epidemiology of _Cryptosporidium_ infection in Spain after the interruption in transmission of _C. hominis_ and the relaxation of COVID-19 containment measures in 2020. ### The Study We searched PubMed, Web of Science, and Scopus databases for molecular studies on human cryptosporidiosis conducted in Spain published during January 2010–December 2020 ([Appendix](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf)). Search terms included _Cryptosporidium_ , human, _hominis_ , _parvum_ , _gp60_ , subtype, and Spain. We identified 7 studies reporting molecular data on _Cryptosporidium_ from laboratory-confirmed clinical samples collected in Spain during 2000‒2016; a total of 806 isolates were characterized ([Appendix](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf) Table). Among _C. hominis_ (76.1%), subtype family Ib predominated (90.7%); subtype IbA10G2 accounted for 99.6% of isolates. Among _C. parvum_ (24.0%), subtype family IIa predominated (87.1%), followed by IIn (7.3%) and IId (5.2%). During December 2013–December 2019, we collected _Cryptosporidium_ -positive clinical fecal samples routinely submitted for genotyping to the National Reference Laboratory at the Spanish National Centre for Microbiology from 7 regions ([Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1)). We obtained additional prepandemic samples through a dedicated multicenter nonoutbreak study across 4 tertiary hospitals in 2 regions ([Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1)). During March–December 2023, we collected postpandemic _Cryptosporidium_ -positive clinical samples through a dedicated multicenter nonoutbreak study across 8 tertiary hospitals in 2 regions ([Table 2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t2)). Upon receipt, all samples were subjected to confirmatory testing and genotyping at the _gp60_ marker in accordance with established protocols and current subtype nomenclature recommendations ([_7_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r7 "7"),[_8_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r8 "8")). We considered only samples identified as _C. hominis_ or _C. parvum_ in our analysis. Our analysis included 389 prepandemic clinical samples ([Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1)). Among _C. hominis_ (85.3%), subtype family Ib predominated (96.7%); subtype IbA10G2 accounted for 96.6% of isolates. Among _C. parvum_ (14.7%), subtype family IIa was most common (59.6%), followed by IId (36.8%) and IIc (3.5%). Our analysis included 126 postpandemic clinical samples ([Table 2](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t2)). Among _C. hominis_ (96.0%), the most common subtype families were If (70.2%) and Ib (22.3%). All If isolates belonged to subtype IfA12G1R5, whereas IbA10G2 represented 7.4% and IbA13G3 represented 88.9% of isolates within subtype family Ib. _C. parvum_ accounted for the remaining 4.0% of isolates, all of which belonged to subtype family IIa. The distribution of _C. hominis_ subtypes in 2023 differed markedly from that observed during 2000–2019, both in diversity (10 vs. 2–5 subtypes) and frequency rates, as determined by comparison to clinical samples genotyped at the National Reference Laboratory and deposited to GenBank during 2013‒2023 ([Table 3](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t3)). Subtype IfA12G1R5 accounted for 67.5% of cases despite being detected only once previously, whereas the historically predominant subtype IbA10G2 declined dramatically from 79.7% to 1.6%. _C. parvum_ was rarely detected in 2023. [Top](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article) ### Conclusions Before the COVID-19 pandemic (2000–2019), _C. hominis_ was the predominant species in Spain, accounting for ≈76%–85% of cases; subtype family Ib was overwhelmingly dominant (91%–97%) ([Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1); [Appendix](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf) Table). Within family Ib, IbA10G2 was most frequently identified across multiple studies and settings (97%–99%), suggesting a well-established and stable anthroponotic transmission network. _C. parvum_ accounted for a smaller percentage of infections; family IIa predominated, particularly IIaA15G2R1 ([Table 1](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t1); [Appendix](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-app1.pdf) Table). That pattern is consistent with ongoing zoonotic transmission linked to livestock or wildlife exposure. The COVID-19 pandemic appears to have altered this equilibrium. Evidence from several countries indicates that nonpharmaceutical interventions disproportionally affected _C. hominis_ , whose transmission relies primarily on person-to-person contact and common-source exposures. Indeed, postpandemic reductions or even interruptions in _C. hominis_ transmission have been reported in England and Wales ([_3_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r3 "3"),[_4_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r4 "4")), New Zealand ([_6_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r6 "6")), Scotland ([_5_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r5 "5")), and Sweden ([_9_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r9 "9")). In contrast, transmission of the largely zoonotic _C. parvum_ remained comparatively stable, as observed in New Zealand ([_6_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r6 "6")). A similar pattern appears to have occurred in Spain, where all _Cryptosporidium_ -positive samples detected immediately after the pandemic were identified as _C. parvum_ , with no evidence of _C. hominis_ circulation in the investigated population ([_7_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r7 "7")). The postpandemic resurgence observed in 2023 ([Table 3](https://wwwnc.cdc.gov/eid/article/32/12/26-1007-t3)), after interruption of _C. hominis_ transmission ([_7_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r7 "7")), was accompanied by an unprecedented increase in cryptosporidiosis cases across Europe ([_10_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r10 "10"),[_11_](https://wwwnc.cdc.gov/eid/article/32/12/26-1007_article#r11 "11")). An additional contributing factor might have been an immunity debt
## Related Clinical Research

- [Maternal and Early-Life Obesity Impairs CD4+ T Cell Programming and Vaccine Responses](https://medichelpline.com/clinical-feed/nature-immunology-1-maternal-and-early-life-obesity-programs-cd4-t-cell-fate-to-impair-vaccine.md)
- [Distinct Maturation-Associated Neutrophil Transcriptional Programs in COVID-19 Versus Tuberculosis](https://medichelpline.com/clinical-feed/biorxiv-2-covid-19-and-active-tuberculosis-exhibit-distinct-maturation-associated.md)
- [Repeated mRNA Vaccination Drives Clonal and Epitope Shifts in CD8+ T Cell Memory](https://medichelpline.com/clinical-feed/biorxiv-11-repeated-exposure-to-a-conserved-antigen-drives-dynamic-clonal-and-epitope.md)
- [Influenza Vaccination Associated with Lower IMV and Death Risk in Older Hospitalized Adults — Fran](https://medichelpline.com/clinical-feed/medrxiv-3-influenza-vaccination-and-disease-severity-among-older-adults-hospitalized-with.md)
- [Epidemiology of acute respiratory infections in adults at Hospices Civils de Lyon (2016–2025)](https://medichelpline.com/clinical-feed/medrxiv-7-epidemiology-of-acute-respiratory-infections-in-adult-patients-in-hospices.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.